Real-world effectiveness of omalizumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP): findings from CHRINOSOR
Volume: 0 - Issue: 0
First page: 0 - Last page: 0
T. Bartosik - S.F. Seys - J. de Kinderen - M. Wagenmann - M. Bruch - A. Andrianakis - X. Gonzalez-Compta - V. Hox - L. Pardo Muñoz - S. Schneider - G. Bettio - M. Burian - J. Eckl-Dorna - M. Golet Fors - G. Mariën - C. Morgenstern - K. Scheckenbach - P-V. Tomazic - A. Tu - S. Allu - Z. Diamant - C. Bachert -
CHRINOSOR Consortium*:
Isam Alobid, Carlo Cavaliere, Wytske Fokkens, Peter W. Hellings, Claire Hopkins, Adriana Izquierdo-Dominguez, Xavier Jaumont, Anette Kjeldsen, Anu Laulajainen-Hongisto, Valerie Lund, Geoffrey Mortuaire, Petter Olsson, Laura Van Gerven, Sietze Reitsma
DOI: 10.4193/Rhin25.514
Omalizumab is a recombinant DNA-derived humanized monoclonal antibody targeting free immunoglobulin E. In the omalizumab phase III studies for chronic rhinosinusitis with nasal polyp (CRSwNP), a clinically relevant reduction of the nasal polyp score (NPS) was observed leading to improved SinoNasal Outcome Test-22 (SNOT-22). In the extension study, sustained or further improvement of symptoms and NPS reduction were observed up to 52 weeks. Real-world data is needed to establish effectiveness in uncontrolled severe CRSwNP, but so far, data on long-term omalizumab treatment is sparse .
Rhinology 0 - 0: 0-0, 0000
To see the issue content and the abstract you do not have to login
Please login to download the full articles
If you do not have a subscription to Rhinology please consider taking one.
